New weekly shot could replace daily HIV pills for some patients

NCT ID NCT02859961

First seen Mar 13, 2026 · Last updated May 16, 2026 · Updated 13 times

Summary

This study tested whether a weekly injection of PRO 140 could keep HIV under control in people whose virus was already suppressed by standard daily pills. Over 500 adults with a specific type of HIV (CCR5-tropic) switched from their usual combination therapy to PRO 140 alone for 48 weeks. The goal was to see if the shot could maintain viral suppression without the need for daily oral medications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CD03 Investigational site

    La Mesa, California, 91942, United States

  • CD03 Investigational site

    Palm Springs, California, 92262, United States

  • CD03 Investigational site

    San Francisco, California, 94115, United States

  • CD03 Investigational site

    New Haven, Connecticut, 06510, United States

  • CD03 Investigational site

    Norwalk, Connecticut, 06850, United States

  • CD03 Investigational site

    Ft. Pierce, Florida, 34982, United States

  • CD03 Investigational site

    Orlando, Florida, 32803, United States

  • CD03 Investigational site

    West Palm Beach, Florida, 33401, United States

  • CD03 Investigational site

    Wichita, Kansas, 67214, United States

  • CD03 Investigational site

    Las Vegas, Nevada, 89109, United States

  • CD03 Investigational site

    New York, New York, 10011, United States

  • CD03 Investigational site

    Syracuse, New York, 13210, United States

Conditions

Explore the condition pages connected to this study.